Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15916429rdf:typepubmed:Citationlld:pubmed
pubmed-article:15916429lifeskim:mentionsumls-concept:C0001962lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C0033681lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C1150423lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C0870071lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:15916429lifeskim:mentionsumls-concept:C1514873lld:lifeskim
pubmed-article:15916429pubmed:issue11lld:pubmed
pubmed-article:15916429pubmed:dateCreated2005-5-26lld:pubmed
pubmed-article:15916429pubmed:abstractTextUtilizing our recently published semisynthetic approach to the (3'S)-K-252a diastereomer, we report the first synthesis of the (3'R)-10 diastereomer and a set of related epimers, with the goal of defining the stereochemical role of the 3'-sugar hydroxyl group on trkA tyrosine kinase activity and selectivity. (3'R)-10 displayed potent trkA inhibitory activity with an IC50 value of 4 nM. The corresponding deshydroxy epimer (3'S)-14 was 7-fold more potent than its 3'R counterpart (natural stereochemistry) with a trkA IC50 value of 3 nM and demonstrated >280-fold selectivity over PKC (IC50 = 850 nM). In cells, (3'S)-14 displayed potent inhibition of trkA autophosphorylation with an IC50 < 10 nM. Molecular modeling studies revealed that the 3'-OH, due to the inverted geometry, forms significant H-bonding interactions with Glu27 and Arg195, an interaction that is not attainable with the natural isomers.lld:pubmed
pubmed-article:15916429pubmed:languageenglld:pubmed
pubmed-article:15916429pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:citationSubsetIMlld:pubmed
pubmed-article:15916429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15916429pubmed:statusMEDLINElld:pubmed
pubmed-article:15916429pubmed:monthJunlld:pubmed
pubmed-article:15916429pubmed:issn0022-2623lld:pubmed
pubmed-article:15916429pubmed:authorpubmed-author:AngelesThelma...lld:pubmed
pubmed-article:15916429pubmed:authorpubmed-author:HudkinsRobert...lld:pubmed
pubmed-article:15916429pubmed:authorpubmed-author:GingrichDiane...lld:pubmed
pubmed-article:15916429pubmed:authorpubmed-author:YangShi XSXlld:pubmed
pubmed-article:15916429pubmed:authorpubmed-author:GessnerGeorge...lld:pubmed
pubmed-article:15916429pubmed:issnTypePrintlld:pubmed
pubmed-article:15916429pubmed:day2lld:pubmed
pubmed-article:15916429pubmed:volume48lld:pubmed
pubmed-article:15916429pubmed:ownerNLMlld:pubmed
pubmed-article:15916429pubmed:authorsCompleteYlld:pubmed
pubmed-article:15916429pubmed:pagination3776-83lld:pubmed
pubmed-article:15916429pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:meshHeadingpubmed-meshheading:15916429...lld:pubmed
pubmed-article:15916429pubmed:year2005lld:pubmed
pubmed-article:15916429pubmed:articleTitleSynthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on trkA tyrosine kinase activity.lld:pubmed
pubmed-article:15916429pubmed:affiliationDepartment of Medicinal Chemistry, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, USA.lld:pubmed
pubmed-article:15916429pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:15916429lld:chembl